GT Biopharma Clears FDA Hurdle for Multiple Myeloma Trial of GTB-5550
Event summary
- FDA cleared a new IND for GTB-5550 in multiple myeloma under an investigator-sponsored trial protocol.
- Phase 1 trial initiation contingent on securing non-dilutive grant funding.
- Unaudited proforma cash balance of $11M expected to last into Q3 2027.
- Phase 1 dose escalation basket trial in solid tumors actively enrolling, with Q4 2026 update anticipated.
The big picture
GT Biopharma's expansion into multiple myeloma with GTB-5550 highlights the versatility of its TriKE® platform, targeting an area of unmet need in later-line patients. The move comes as B7-H3 remains a hotspot for immuno-oncology development, though most competitors focus on solid tumors. The company's ability to leverage non-dilutive funding will be critical to advancing this new indication.
What we're watching
- Funding Timelines
- Whether GT Biopharma can secure non-dilutive grant funding to initiate the Phase 1 trial in multiple myeloma.
- Clinical Efficacy
- The pace at which preliminary anti-tumor activity data emerges from the Phase 1a/1b trial.
- Competitive Positioning
- How GTB-5550's subcutaneous administration differentiates it in the B7-H3-targeted therapy landscape.